Updated Japanese Urological Association Guidelines on prostate-specific antigen-based screening for prostate cancer in 2010

International Journal of Urology

Volumn 17, Issue 10, 2010, Pages 830-838

  Naito, Seiji ^a   Kakehi, Yoshiyuki ^a   Okuyama, Akihiko ^a   Imamura, Tomoaki ^a   Yasunaga, Hideo ^a   Akaza, Hideyuki ^a   Hinotsu, Shiro ^a   Arai, Yoichi ^a   Dokiya, Takushi ^a   Egawa, Shin ^a   Suzuki, Kazuhiro ^a   Koga, Hirofumi ^a   Masumori, Naoya ^a   Akakura, Koichiro ^a   Kawashima, Kiyotaka ^a   Okihara, Koji ^a   Ito, Kazuto ^a  

^a NONE

Author keywords

guidelines; prostate cancer; PSA; screening

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CANCER MORTALITY; CANCER SCREENING; CLINICAL PROTOCOL; DISEASE SEVERITY; HEALTH CARE POLICY; HIGH RISK POPULATION; HUMAN; INFORMED CONSENT; JAPAN; MEDICAL DECISION MAKING; MEDICAL SOCIETY; MEDICOLEGAL ASPECT; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; SCREENING TEST; THEORETICAL STUDY; UNITED STATES;

EARLY DETECTION OF CANCER; HUMANS; JAPAN; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK ASSESSMENT;

EID: 77957285276     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2010.02613.x     Document Type: Review

References (29)

1. Schröder FH, Hugosson J, Roobol MJ et al. Screening and prostate-cancer mortality in a randomized European study. N. Engl. J. Med. 2009 360 : 1320 8.
2. Cancer Registration Committee of the Japanese Urological Association. Clinicopathological statistics on registered prostate cancer patients in Japan: 2000 report from the Japanese Urological Association. Int. J. Urol. 2005 12 : 46 61.
3. Ito K, Yamamoto T, Takechi H et al. Impact of exposure rate of PSA-screening on clinical stage of prostate cancer in Japan. J. Urol. 2006 175 (Suppl. 477 8.
4. Ministry of Health, Labour and Welfare. Vital statistics in 2008 (Statistics and Information Department Minister's Secretariat Ministry of Health, Labour and Welfare, Japan): Table 6. The number of mortality and mortality rate stratified by sex and cause of death (in Japanese). [Cited on July 30, 2010.] Available from URL: http://www.mhlw.go.jp/toukei/saikin/hw/ jinkou/geppo/nengai08/toukei6.html
5. Kuroishi T, Hirose K, Tominaga Y, Aoki K, Tajima K. Prediction of the future mortality of cancer in Japan. In : Oshima A, Kuroishi T, Tajima K (eds). White Paper on Cancer and Statistics- Incidence/Mortality/Prognosis-2004. Shinohara-shuppan
6. Roobol MJ, Kerkhof M, Schröder FH et al. Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC). Eur. Urol. 2009 56 : 584 91.
7. Sirovich BE, Schwartz LM, Woloshin S. Screening men for prostate and colorectal cancer in the United States: does practice reflect the evidence? JAMA 2003 289 : 1414 20. (Pubitemid 37430309)
8. Jemal A, Siegel R, Ward E et al. Cancer statistics 2009. CA Cancer J. Clin. 2009 59 : 225 49.
9. Bartsch G, Horninger W, Klocker H et al. Tyrol prostate cancer demonstration project: early detection, treatment, outcome, incidence and mortality. BJU Int. 2008 101 : 809 16. (Pubitemid 351347736)
10. Andriole GL, Grubb RL III., Buys SS et al. Mortality results from a randomized prostate-cancer screening trial. N. Engl. J. Med. 2009 360 : 1310 19.
11. Colloi JL, Amling CL. Prostate cancer mortality rates compared to urologist population densities and prostate-specific antigen screening levels on a state-by-state basis in the United States of America. Prostate Cancer Prostatic Dis. 2008 11 : 247 51.
12. Ito K. Prostate-specific antigen-based screening for prostate cancer: evidence, controversies and future perspectives. Int. J. Urol. 2009 16 : 458 64.
13. Aus G, Bergdahl S, Lodding P, Lilja H, Hugosson J. Prostate cancer screening decreases the absolute risk of being diagnosed with advanced prostate cancer - results from a prospective, population-based randomized controlled trial. Eur. Urol. 2007 51 : 659 64. (Pubitemid 46110933)
14. D'Amico AV, Renshaw AA, Sussman B, Chen MH. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA 2005 294 : 440 7. (Pubitemid 41124176)
15. D'Amico AV, Chen MH, Roehl KA, Catalona WJ. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N. Engl. J. Med. 2004 351 : 125 35.
16. Ito K, Yamamoto T, Ohi M et al. Usefulness of age-specific reference range of prostate-specific antigen for Japanese men older than 60 years in mass screening for prostate cancer. Urology 2000 56 : 278 82. (Pubitemid 30495583)
17. Ito K, Yamamoto T, Ohi M et al. Cumulative probability of PSA increase above 4.0 ng/mL in population based screening for prostate cancer. Int. J. Cancer 2004 109 : 455 60. (Pubitemid 38252777)
18. Ito K, Yamamoto T, Ohi M et al. Possibility of re-screening intervals of more than one year in men with PSA levels of 4.0 ng/mL or less. Prostate 2003 57 : 8 13. (Pubitemid 37070144)
19. Ito K, Yamamoto T, Suzuki K, Kurokawa K, Yamanaka H. The risk of rapid prostate specific antigen increase in men with baseline prostate specific antigen 2.0 ng/mL or less. J. Urol. 2004 171 : 656 60. (Pubitemid 38090450)
20. Kakehi Y, Naito S, Japanese Urological Association. Complication rates of ultrasound-guided prostate biopsy: a nation-wide survey in Japan. Int. J. Urol. 2008 15 : 319 21. (Pubitemid 351490162)
21. Klotz L. Active surveillance with selective delayed intervention for favorable risk prostate cancer. Urol. Oncol. 2006 24 : 46 50. (Pubitemid 43097357)
22. Kakehi Y, Kamoto T, Shiraishi T et al. Prospective evaluation of selection criteria for active surveillance in Japanese patients with stage T1cN0M0 prostate cancer. Jpn J. Clin. Oncol. 2008 38 : 122 28. (Pubitemid 351337956)
23. van den Bergh CN, Roemeling S, Roobol MJ et al. Prospective validation of active surveillance in prostate cancer: the PRIAS study. Eur. Urol. 2007 52 : 1560 3. (Pubitemid 350052404)
24. van den Bergh RC, Vasarainen H, van der Poel HG et al. Short-term outcomes of the prospective multicentre "Prostate Cancer Research International: active Surveillance" study. BJU Int. 2010 105 : 956 62.
25. Roemeling S, Roobol MJ, Postma R et al. Management and survival of screen-detected prostate cancer patients who might have been suitable for active surveillance. Eur. Urol. 2006 50 : 475 82. (Pubitemid 44189069)
26. van den Bergh RC, Roemeling S, Roobol MJ et al. Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantly. Eur. Urol. 2009 55 : 1 8.
27. American Urological Association. Prostate-Specific Antigen Best Practice Statement: 2009 Update Cited on July 30, 2010.] Available from URL: http://www.auanet.org/content/guidelines-and-quality-care/clinical-guidelines/ main-reports/psa09.pdf
28. Suzuki H, Flanigan RC, Okuyama A. Prostate specific antigen (PSA)-based screening. Int. J. Urol. 2008 15 : 757 62.
29. Ito K, Kakehi Y, Naito S, Okuyama A, Japanese Urological Association. Japanese Urological Association guidelines on prostate-specific antigen-based screening for prostate cancer and the ongoing cluster cohort study in Japan. Int. J. Urol. 2008 15 : 763 8.